![]() | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
| "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2020-12-15 Purchase | 2020-12-17 5:39 pm | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 425,000 | $23 | $9,775,000 | 1,060,880 (Indirect Direct) | View |
2020-12-15 Purchase | 2020-12-17 5:40 pm | 4D Molecular Therapeutics Inc. | FDMT | Kamal Fariborz See Remarks | 4,347 | $23 | $99,981 | 4,347 (Direct) | View |
2020-12-15 Purchase | 2020-12-17 5:40 pm | 4D Molecular Therapeutics Inc. | FDMT | MILLIGAN JOHN F Director | 100,000 | $23 | $2,300,000 | 100,000 (Indirect) | View |
2020-12-15 Purchase | 2020-12-17 9:15 pm | 4D Molecular Therapeutics Inc. | FDMT | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 1,100,000 | $23 | $25,300,000 | 3,937,914 (Indirect) | View |
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 2,864 | $0 | 1,060,880 (Direct) | View |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 455,326 | $0 | 1,060,880 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 180,554 | $0 | 1,060,880 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 2,864 | $0 | 1,060,880 (Direct) | View |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 455,326 | $0 | 1,060,880 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 5:39 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | YAO TONY DUNG LING Director | 180,554 | $0 | 1,060,880 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 9:15 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 2,004,581 | $0 | 3,937,914 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 9:15 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 833,333 | $0 | 3,937,914 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 9:15 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 2,004,581 | $0 | 3,937,914 (Indirect) | View |
2020-12-15 Conversion | 2020-12-17 9:15 pm | N/A N/A | 4D Molecular Therapeutics Inc. | FDMT | VIKING GLOBAL INVESTORS LP Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Global Opportunities Portfolio GP LLC Viking Global Opportunities GP LLC HALVORSEN OLE ANDREAS Ott David C. Shabet Rose Sharon 10% Owner | 833,333 | $0 | 3,937,914 (Indirect) | View |